2025年4月6日 周日
Home > Archive>Volume 29, Issue 6, 2021 >461-467
PDF HTML XML Export Cite reminder
The clinical progresses in interventional therapy of coronary heart disease
CSTR:
[cstr]
Author:
Affiliation:

1.Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China;2.The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, Heilongjiang 150001, China)

  • Article
    • | |
  • Metrics
    • |
  • Reference [80]
    • |
  • Related [20]
    • | | |
  • Comments
    Reference
    [1] KOVACIC JC, FUSTER V.From treating complex coronary artery disease to promoting cardiovascular health:therapeutic transitions and challenges, 2010-2020.Clin Pharmacol Ther, 1,0(4):509-518.
    [2] AHMAD Y, HOWARD J P, ARNOLD A D, et al.Mortality after drug-eluting stents vs.coronary artery bypass grafting for left main coronary artery disease:a meta-analysis of randomized controlled trials.Eur Heart J, 0,1(34):3228-3235.
    [3] PARK D W, AHN J M, PARK H, et al.Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease:extended follow-up of the PRECOMBAT trial.Circulation, 0,1(18):1437-1446.
    [4] HOLM N R, MKIKALLIO T, LINDSAY M M, et al.Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis:updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.Lancet(London, England), 0,5(10219):191-199.
    [5] KUNO T, UEYAMA H, RAO S V, et al.Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease:a meta-analysis of randomized trials.Am Heart J, 0,7:9-10.
    [6] CHEN S L, ZHANG J J, HAN Y, et al.Double kissing crush versus provisional stenting for left main distal bifurcation lesions:DKCRUSH-V randomized trial.J Am Coll Cardiol, 7,0(21):2605-2617.
    [7] GOLDSTEIN J A, DEMETRIOU D, GRINES C L, et al.Multiple complex coronary plaques in patients with acute myocardial infarction.N Engl J Med, 0,3(13):915-922.
    [8] VOGEL B, MEHTA S R, MEHRAN R.Reperfusion strategies in acute myocardial infarction and multivessel disease.Nat Rev Cardiol, 7,4(11):665-678.
    [9] JEGER R, JAGUSZEWSKI M, NALLAMOTHU B N, et al.Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction:a nationwide study cohort from the AMIS plus registry.Int J Cardiol, 4,2(1):76-81.
    [10] GARG P, NORMAND S L, SILBAUGH T S, et al.Drug-eluting or bare-metal stenting in patients with diabetes mellitus:results from the Massachusetts Data Analysis Center Registry.Circulation, 8,8(22):2277-2285.
    [11] PASCERI V, PATTI G, SPECIALE G, et al.Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction.Am Heart J, 7,3(5):749-754.
    [12] WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med, 7,7(20):2001-2015.
    [13] WALLENTIN L, BECKER R C, BUDAJ A, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med, 9,1(11):1045-1057.
    [14] WOOD D A, CAIRNS J A, WANG J, et al.Timing of staged nonculprit artery revascularization in patients with ST-segment elevation myocardial infarction:COMPLETE trial.J Am Coll Cardiol, 9,4(22):2713-2723.
    [15] MARENZI G, ASSANELLI E, CAMPODONICO J, et al.Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.Ann Intern Med, 9,0(3):170-177.
    [16] AMBROSE J A, WEINRAUCH M.Thrombosis in ischemic heart disease.Arch Intern Med, 6,6(13):1382-1394.
    [17] BARRETT T D, HENNAN J K, MARKS R M, et al.C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion.J Pharmacol Exp Ther, 2,3(3):1007-1013.
    [18] HEUSCH G, KLEINBONGARD P, BSE D, et al.Coronary microembolization:from bedside to bench and back to bedside.Circulation, 9,0(18):1822-1836.
    [19] ROE M T, CURA F A, JOSKI P S, et al.Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction.Am J Cardiol, 1,8(2):170-173.
    [20] HANRATTY C G, KOYAMA Y, RASMUSSEN H H, et al.Exaggeration of nonculprit stenosis severity during acute myocardial infarction:implications for immediate multivessel revascularization.J Am Coll Cardiol, 2,0(5):911-916.
    [21] 赵帅, 张政, 汪钦, 等.PCI对多支病变冠心病患者部分血运重建后短期生活质量的影响.中国动脉硬化杂志, 1,9(6):468-475.
    [22] BRILAKIS E S, MASHAYEKHI K, TSUCHIKANE E, et al.Guiding principles for chronic total occlusion percutaneous coronary intervention.Circulation, 9,0(5):420-433.
    [23] OBEDINSKIY A A, KRETOV E I, BOUKHRIS M, et al.The IMPACTOR-CTO trial.JACC Cardiovasc Interv, 8,1(13):1309-1311.
    [24] ALLAHWALA U K, WARD M R, BRIEGER D, et al.Indications for percutaneous coronary intervention(PCI) in chronic total occlusion(CTO):have we reached a decision or do we continue to explore after EURO-CTO.Heart Lung Circ, 9,8(10):1484-1489.
    [25] ELLIS S G, VANDORMAEL M G, COWLEY M J, et al.Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.Implications for patient selection.Multivessel Angioplasty Prognosis Study Group.Circulation, 0,2(4):1193-1202.
    [26] BRILAKIS E S, GRANTHAM J A, RINFRET S, et al.A percutaneous treatment algorithm for crossing coronary chronic total occlusions.JACC Cardiovasc Interv, 2,5(4):367-379.
    [27] FUJINO A, OTSUJI S, HASEGAWA K, et al.Accuracy of J-CTO score derived from computed tomography versus angiography to predict successful percutaneous coronary intervention.JACC Cardiovasc Imaging, 8,1(2 Pt 1):209-217.
    [28] 王凯阳, 吴婷婷, 郑颖颖, 等.冠状动脉慢性完全闭塞病变患者PCI手术预后模型的建立.中国动脉硬化杂志, 1,9(6):475-482.
    [29] VIRMANI R, KOLODGIE F D, BURKE A P, et al.Lessons from sudden coronary death:a comprehensive morphological classification scheme for atherosclerotic lesions.Thromb Vasc Biol, 0,0(5):1262-1275.
    [30] VIRMANI R, BURKE A P, FARB A, et al.Pathology of the vulnerable plaque.J Am Coll Cardiol, 6,7(8 Suppl):C13-C18.
    [31] MAUROVICH-HORVAT P, SCHLETT C L, ALKADHI H, et al.Differentiation of early from advanced coronary atherosclerotic lesions:systematic comparison of CT, intravascular US, and optical frequency domain imaging with histopathologic examination in ex vivo human hearts.Radiology, 2,5(2):393-401.
    [32] CHOI B J, MATSUO Y, AOKI T, et al.Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis.Thromb Vasc Biol, 4,4(11):2473-2477.
    [33] BEZERRA H G, COSTA M A, GUAGLIUMI G, et al.Intracoronary optical coherence tomography:a comprehensive review clinical and research applications.JACC Cardiovasc Interv, 9,2(11):1035-1046.
    [34] KUBO T, XU C, WANG Z, et al.Plaque and thrombus evaluation by optical coherence tomography.Int J Cardiovasc Imaging, 1,7(2):289-298.
    [35] KWAN T W, YANG S, XU B, et al.Optimized quantitative angiographic and intravascular ultrasound parameters predicting the functional significance of single de novo lesions in the left anterior descending artery.Chin Med J (Engl), 2,5(23):4249-4253.
    [36] KANG S J, MINTZ G S, PARK D W, et al.Mechanisms of in-stent restenosis after drug-eluting stent implantation:intravascular ultrasound analysis.Circ Cardiovasc Interv, 1,4(1):9-14.
    [37] KALIDINDI S R, TUZCU E M, NICHOLLS S J.Role of imaging end points in atherosclerosis trials:focus on intravascular ultrasound.Int J Clin Pract, 7,1(6):951-962.
    [38] HACHINOHE D, MITOMO S, CANDILIO L, et al.A practical approach to assessing stent results with IVUS or OCT.Methodist Debakey Cardiovasc J, 8,4(1):32-41.
    [39] MINTZ G S, GUAGLIUMI G.Intravascular imaging in coronary artery disease.Lancet (London, England), 7,0(10096):793-809.
    [40] WITZENBICHLER B, MAEHARA A, WEISZ G, et al.Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents:the assessment of dual antiplatelet therapy with drug-eluting stents(ADAPT-DES) study.Circulation, 4,9(4):463-470.
    [41] ZHANG J, GAO X, KAN J, et al.Intravascular ultrasound versus angiography-guided drug-eluting stent implantation:The ULTIMATE trial.J Am Coll Cardiol, 8,2(24):3126-3137.
    [42] FEARON W F, NISHI T, DE BRUYNE B, et al.Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease:three-year follow-up of the FAME 2 trial(fractional flow reserve versus angiography for multivessel evaluation).Circulation, 8,7(5):480-487.
    [43] GTBERG M, COOK C M, SEN S, et al.The evolving future of instantaneous wave-free ratio and fractional flow reserve.J Am Coll Cardiol, 7,0(11):1379-1402.
    [44] BURZOTTA F, LEONE A M, AURIGEMMA C, et al.Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis:a single-center trial.JACC Cardiovasc Interv, 0,3(1):49-58.
    [45] BECH G J, DE BRUYNE B, PIJLS N H, et al.Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis:a randomized trial.Circulation, 1,3(24):2928-2934.
    [46] TONINO P A, DE BRUYNE B, PIJLS N H, et al.Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.N Engl J Med, 9,0(3):213-224.
    [47] DE BRUYNE B, PIJLS N H, KALESAN B, et al.Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.N Engl J Med, 2,7(11):991-1001.
    [48] FOURNIER S, CICCARELLI G, TOTH G G, et al.Association of improvement in fractional flow reserve with outcomes, including symptomatic relief, after percutaneous coronary intervention.JAMA Cardiol, 9,4(4):370-374.
    [49] VAN NUNEN L X, ZIMMERMANN F M, TONINO P A, et al.Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease(FAME):5-year follow-up of a randomised controlled trial.Lancet (London, England), 5,6(10006):1853-1860.
    [50] DAVIES J E, SEN S, DEHBI H M, et al.Use of the instantaneous wave-free ratio or fractional flow reserve in PCI.N Engl J Med, 7,6(19):1824-1834.
    [51] GTBERG M, CHRISTIANSEN E H, GUDMUNDSDOTTIR I J, et al.Instantaneous wave-free ratio versus fractional flow reserve to guide PCI.N Engl J Med, 7,6(19):1813-1823.
    [52] SMITS P C, LAFORGIA P L, ABDEL-WAHAB M, et al.Fractional flow reserve-guided multivessel angioplasty in myocardial infarction:three-year follow-up with cost benefit analysis of the compare-acute trial.EuroIntervention, 0,6(3):225-232.
    [53] KYHL K, AHTAROVSKI K A, NEPPER-CHRISTENSEN L, et al.Complete revascularization versus culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease:a DANAMI-3-PRIMULTI cardiac magnetic resonance substudy.JACC Cardiovasc Interv, 9,2(8):721-730.
    [54] CUTLIP D E, CHAUHAN M S, BAIM D S, et al.Clinical restenosis after coronary stenting:perspectives from multicenter clinical trials.J Am Coll Cardiol, 2,0(12):2082-2089.
    [55] MONGIARDO A, CURCIO A, SPACCAROTELLA C, et al.Molecular mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy.Curr Drug Targets Cardiovasc Haematol Disord, 4,4(3):275-287.
    [56] INDOLFI C, DE ROSA S, COLOMBO A.Bioresorbable vascular scaffolds-basic concepts and clinical outcome.Nat Rev Cardiol, 6,3(12):719-729.
    [57] STONE G W, ELLIS S G, GORI T, et al.Blinded outcomes and angina assessment of coronary bioresorbable scaffolds:30-day and 1-year results from the ABSORB IV randomised trial.Lancet(London, England), 8,2(10157):1530-1540.
    [58] SERRUYS P W, CHEVALIER B, DUDEK D, et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet(London, England), 5,5(9962):43-54.
    [59] DILETTI R, SERRUYS P W, FAROOQ V, et al.ABSORB Ⅱ randomized controlled trial:a clinical evaluation to compare the safety, efficacy, and performance of the absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions:rationale and study design.Am Heart J, 2,4(5):654-663.
    [60] GAO R, YANG Y, HAN Y, et al.Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial.J Am Coll Cardiol, 5,6(21):2298-2309.
    [61] KIMURA T, KOZUMA K, TANABE K, et al.A randomized trial evaluating everolimus-eluting absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan.Eur Heart J, 5,6(47):3332-3342.
    [62] ALI ZA, GAO R, KIMURA T, et al.Three-year outcomes with the absorb bioresorbable scaffold:individual-patient-data meta-analysis from the ABSORB randomized trials.Circulation, 8,7(5):464-479.
    [63] KEREIAKES D J, ELLIS S G, METZGER D C, et al.Clinical outcomes before and after complete everolimus-eluting bioresorbable scaffold resorption:five-year follow-up from the ABSORB Ⅲ trial.Circulation, 9,0(23):1895-1903.
    [64] RBER L, UEKI Y.Bioresorbable scaffolds:unfulfilled prophecies.Circulation, 9,0(23):1917-1920.
    [65] LEVINE G N, BATES E R, BITTL J A, et al.2016 ACC/AHA Guideline Focused Update On Duration Of Dual Antiplatelet Therapy In Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines:An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.Circulation, 6,4(10):e123-e155.
    [66] COLLET C, ASANO T, MIYAZAKI Y, et al.Late thrombotic events after bioresorbable scaffold implantation:a systematic review and meta-analysis of randomized clinical trials.Eur Heart J, 7,8(33):2559-2566.
    [67] FELIX C M, VLACHOJANNIS G J, AJJ I J, et al.Potentially increased incidence of scaffold thrombosis in patients treated with absorb BVS who terminated DAPT before 18 months.EuroIntervention, 7,3(2):e177-e184.
    [68] 荀一骊, 吴婷婷, 郑颖颖, 等.平均血小板体积与血小板计数比值对冠心病PCI术后临床结局的影响:一项回顾性队列研究.中国动脉硬化杂志, 1,9(6):483-488.
    [69] MEHTA S R, YUSUF S, PETERS R J, et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study.Lancet(London, England), 1,8(9281):527-533.
    [70] YEH R W, KEREIAKES D J, STEG P G, et al.Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction.J Am Coll Cardiol, 5,5(20):2211-2221.
    [71] VALGIMIGLI M, COSTA F, LOKHNYGINA Y, et al.Trade-off of myocardial infarction vs.bleeding types on mortality after acute coronary syndrome:lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome(TRACER) randomized trial.Eur Heart J, 7,8(11):804-810.
    [72] VRANCKX P, VALGIMIGLI M, JNI P, et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre, open-label, randomised superiority trial.Lancet(London, England), 8,2(10151):940-949.
    [73] BABER U, DANGAS G, ANGIOLILLO D J, et al.Ticagrelor alone vs.ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes:TWILIGHT-ACS.Eur Heart J, 0,1(37):3533-3545.
    [74] TOMANIAK M, CHICHAREON P, ONUMA Y, et al.Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes:a post hoc analysis of the randomized global leaders trial.JAMA Cardiol, 9,4(11):1092-1101.
    [75] HAHN J Y, SONG Y B, OH J H, et al.Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial.JAMA, 9,1(24):2428-2437.
    [76] SOPPERT J, LEHRKE M, MARX N, et al.Lipoproteins and lipids in cardiovascular disease:from mechanistic insights to therapeutic targeting.Adv Drug Deliv Rev, 0,9:4-33.
    [77] DURAN E K, ADAY A W, COOK N R, et al.Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease.J Am Coll Cardiol, 0,5(17):2122-2135.
    [78] BALLING M, AFZAL S, VARBO A, et al.VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins.J Am Coll Cardiol, 0,6(23):2725-2735.
    [79] BITTNER V A, SZAREK M, AYLWARD P E, et al.Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome.J Am Coll Cardiol, 0,5(2):133-144.
    [80] 杨云潇, 张铭.甲状腺功能减退症与动脉粥样硬化的研究新进展.中国动脉硬化杂志, 1,9(6):489-493.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

JIA Ying, TIAN Yanan, TIAN Jinwei. The clinical progresses in interventional therapy of coronary heart disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(6):461-467.

Copy
Share
Article Metrics
  • Abstract:485
  • PDF: 673
  • HTML: 0
  • Cited by: 0
History
  • Received:January 24,2021
  • Revised:March 26,2021
  • Online: June 11,2021
Article QR Code

You are the 27962 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025